Life sciences is at a crossroads. AI leaders promise that their models will eradicate disease, but pharma executives are struggling to integrate AI into the simplest lab workflows.

What’s the gap? At Medra, we believe the answer is simple: we need more data.

AI can’t cure disease without it. Foundation models like AlphaFold2 are groundbreaking, yet they were trained on 50 years of painstakingly collected protein structures, and that dataset is still less than 0.3% the size of what powers multimodal reasoning models like ChatGPT.

We desperately need more foundation models for therapeutic areas like oncology, CNS, genetic medicine, and rare diseases. It doesn’t matter if you’re bringing novel therapeutics to market or training the next scientific frontier model. We all need more experimental throughput, faster.

That's why we're launching Medra. We've built AI specifically for the lab, designed to generate more data, and ultimately lead to more breakthroughs.

Continuous Science Platform

By combining the flexibility of general purpose robots with the scientific reasoning of large language models, we’ve developed a better way to run experiments at scale.

We call it the Continuous Science Platform. It’s a self-improving, closed loop system made up of two parts: Medra’s Physical AI and Scientific AI.

Our Physical AI acts. Our agents have the visual and language understanding to flexibly automate 70% of instruments that scientists already use. They capture images, log every motion, and measure each action taken during a protocol, from the timing of when reagents are mixed to the angle at which pipette tips enter test tubes. This type of granular experimentation data has never been captured at scale before.

Our Scientific AI learns. It analyzes the granular experimentation data and real-world experimental results, suggesting protocol optimizations for the Physical AI to execute. Our Scientific AI and Physical AI work together to form a continuous loop, searching for parameters and converging on an optimal protocol.

Both components work in tandem to scale experiments, and rapidly accelerate scientific discoveries.

Speeding up discoveries

We’re already partnering with some of the world’s largest biotech and pharma companies, pioneering cutting-edge science. Medra’s Continuous Science Platform is helping them get results more quickly, not only by speeding up their experiments but improving them too.

Additionally, we’re proud to also announce our first case studies with the following customers, with whom we're partnering to bring AI directly into the lab.

• Addition Therapeutics - a gene editing company developing RNA therapeutics where we’re supporting with RNA transfection
• Lila Sciences - a scientific super intelligence platform where we’re supporting with protein characterization workflows‍

We’re also partnering with other customers on projects working on antibody engineering, characterizing bacteria and fungi, cell and protein purification, and more.

We are excited to build new AI labs and empower scientists to make breakthroughs faster. If you’re on the same mission, let’s connect.